Novartis delivers solid sales and profit growth. Strong performance of in-market brands supports confidence in mid-term growth outlook

Ad hoc announcement pursuant to Art. 53 LR

  • Q1 sales grew +5% (cc1, +1% USD), core operating income grew +9% (cc, +3% USD)
    • Innovative Medicines (IM) sales grew +4% (cc, +1% USD) and core operating income +5% (cc, 0% USD)
    • Strong performance of key growth brands including Entresto, Kesimpta, Cosentyx and Zolgensma
    • Sandoz sales grew +8% (cc, +2% USD) and core operating income +26% (cc, +21% USD), benefiting from a lower prior year comparison as …
/by
Sandoz launches generic brimonidine tartrate/timolol maleate eyedrop in US for patients with ocular hypertension, expanding leading ophthalmic portfolio
  • Brimonidine tartrate/timolol maleate combination eyedrop is used to treat elevated eye pressure in patients with ocular hypertension1
  • Ocular hypertension affects over 5% of all adults2; the eye does not properly drain fluid, causing eye pressure to build up3
     
  • Sandoz manufactures high-impact medicines that bring savings to US patients and support the sustainability of the overall US healthcare system

Basel, April 14, 2022 — Sandoz, …

/by
Sandoz extends collaboration agreement to drive cutting-edge digital solutions in global fight against antimicrobial resistance (AMR)
  • Extending existing master services agreement with Ares Genetics, to develop digital platform for development and life cycle management of antibiotics, to January 31, 2025
     
  • Both parties strengthening focus on antibiotic stewardship and planning to engage in AMR surveillance and efforts to repurpose existing antibiotics.
     
  • Collaboration focuses on next-generation sequencing (NGS) and AI-assisted bioinformatics solutions for surveillance and drug repurposing efforts

Basel, April 6, 2022 — …

/by
Sandoz extends collaboration agreement to drive cutting-edge digital solutions in global fight against antimicrobial resistance (AMR)
  • Extending existing master services agreement with Ares Genetics, to develop digital platform for development and life cycle management of antibiotics, to January 31, 2025
     
  • Both parties strengthening focus on antibiotic stewardship and planning to engage in AMR surveillance and efforts to repurpose existing antibiotics.
     
  • Collaboration focuses on next-generation sequencing (NGS) and AI-assisted bioinformatics solutions for surveillance and drug repurposing efforts

Basel, April 6, 2022 — …

/by